Latest Breaking News On - Lady davis - Page 5 : comparemela.com

Objective To determine whether the combined use of glucagon-like peptide-1 (GLP-1) receptor agonists and sodium-glucose cotransporter-2 (SGLT-2) inhibitors is associated with a decreased risk of major adverse cardiovascular events and serious renal events compared with either drug class alone among patients with type 2 diabetes, and to assess the effect of the combination on the individual components of major adverse cardiovascular events, heart failure, and all cause mortality. Design Population based cohort study using a prevalent new-user design, emulating a trial. Setting UK Clinical Practice Research Datalink linked to Hospital Episode Statistics Admitted Patient Care and Office for National Statistics databases. Participants Two prevalent new-user cohorts were assembled between January 2013 and December 2020, with follow-up until the end of March 2021. The first cohort included 6696 patients who started GLP-1 receptor agonists and added on SGLT-2 inhibitors, and the second inc

United kingdomCity ofCanadian institutes of health researchSetting united kingdom clinical practice research datalinkBritish national formularyResearch scholarUnited kingdom clinical practice research datalinkRegulatory agencyResearch data governanceEnglish national health serviceFoundation schemeOffice for national statisticsResearch ethics board of the jewishClinical practice research datalinkResearch ethics boardMcgill university